Background/aims: Sparse literature exists on the challenges and ethical considerations of including people with limited access to healthcare, such as the uninsured and low-income, in clinical research in high-income countries. However, many ethical issues should be considered with respect to working with uninsured and low-income participants in clinical research, including enrollment and retention, ancillary care, and post-trial responsibilities. Attention to the uninsured and low-income is particularly salient in the United States due to the high rates of uninsurance and underinsurance. Thus, we conducted a scoping review on the ethical considerations of biomedical clinical research with uninsured and low-income participants in high-income countries in order to describe what is known and to pinpoint areas of needed research on this issue. Methods: MEDLINE/PubMed, Embase, and Scopus databases were searched using terms that described main concepts of interest (e.g., uninsured, underinsured, access to healthcare, poverty, ethics, compensation, clinical research). Articles were included if they met four inclusion criteria: (1) English, (2) high-income countries context, (3) about research participants who are uninsured or low-income, which limits their access to healthcare, and in biomedical clinical research that either had a prospect of direct medical benefit or was offered to them on the basis of their ill health, and (4) recognizes and/or addresses challenges or ethical considerations of uninsured or low-income participants in biomedical clinical research. Results: The searches generated a total of 974 results. Ultimately, 23 papers were included in the scoping review. Of 23 articles, the majority (n = 19) discussed enrollment and retention of uninsured or low-income participants. Several barriers to enrolling uninsured and low-income groups were identified, including limited access to primary or preventive care; lack of access to institutions conducting trials or physicians with enough time or knowledge about trials; overall lack of trust in the government, research, or medical system; and logistical issues. Considerably fewer articles discussed treatment of these participants during the course of research (n = 5) or post-trial responsibilities owed to them (n = 4). Thus, we propose a research agenda that builds upon the existing literature by addressing three broad questions: (1) What is the current status of uninsured research participants in biomedical clinical research in high-income countries? (2) How should uninsured research participants be treated during and after clinical research? (3) How, if at all, should additional protections for uninsured research participants affect their enrollment? Conclusions: This review reveals significant gaps in both data and thoughtful analysis on how to ethically involve uninsured research participants. To address these gaps, we propose a research agenda to gather needed data and theoretical analysis that addresses three broad research questions.
Introduction
Participation in clinical research can offer individuals with limited access to healthcare an opportunity to receive interventions for conditions that otherwise go untreated; however, these interventions are unproven. Discussions about the ethics of research with participants who lack access to healthcare center almost exclusively on trials in low-and middle-income countries (LMIC). [1] [2] [3] Moreover, existing literature that addresses people who are uninsured or otherwise lack healthcare access in high-income countries (HIC) focuses on community-based and nontherapeutic trials (i.e. educational interventions, natural history studies, survey/questionnaires, etc.). [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However, research participants in HIC who are uninsured or otherwise lack access to healthcare encounter limitations similar to those faced by participants in LMIC. Thus, their inclusion in research raises often overlooked but parallel ethical considerations.
Attention to including the uninsured in clinical research is particularly salient in the United States. A significant proportion of the US population (an estimated 8.8% or 28.2 million in 2016) lacks any insurance coverage, 14 ,15 many more are underinsured, 16 and for the first time since the Affordable Care Act passed in 2010, the uninsurance rate for adults in the United States is on the rise. 17 Moreover, a growing amount of data suggests that the uninsured encounter significant barriers in accessing healthcare, perceive discrimination when receiving treatment, and experience poorer health outcomes for both acute and chronic conditions. [18] [19] [20] [21] [22] [23] [24] [25] [26] We conducted a scoping review on the ethical considerations of biomedical clinical research with uninsured and low-income participants in HIC in order to describe what is known and to pinpoint areas of needed research on this issue. Our review revealed that little attention has been paid to ethical issues regarding research participation of uninsured and low-income participants in HIC. Analyses that do address disadvantaged research participants often mention that minority groups are more likely to be uninsured and have low income, but do not distinguish the effects of socioeconomic status from those of race, ethnicity, linguistic and cultural barriers, historical context, and so on. [27] [28] [29] [30] Even when studies explore the challenges and ethical considerations of working with the uninsured, most only discuss issues regarding enrollment and retention, leaving other ethically challenging issues like ancillary and post-trial care relatively neglected. Building on these results, we propose a research agenda to gather needed data and theoretical analysis, as well as raise attention to uninsured participants in biomedical clinical research.
Methods

Search strategy
A combination of controlled vocabulary terms (i.e. Medical Subject Headings, Emtree) and keywords were searched in the MEDLINE/PubMed, Embase, and Scopus databases in February 2018. Used terms described the main concepts of interest: uninsured, underinsured, access to healthcare, poverty, ethics, compensation, and clinical research (See Appendix A in the online supplementary material for MEDLINE search strategies). The references of eligible papers were also reviewed to identify additional relevant articles.
Selection criteria
We followed PRISMA guidelines for our scoping review (Figure 1) . One author (H.C.) screened the titles and abstracts of results to assess their relevance to the research question. A second author (C.G.) verified the eligibility of the references, including when eligibility was unclear. Articles passed the title/abstract screening if they did not meet any of the exclusion criteria and clearly met at least three of the inclusion criteria. When the eligibility of an article was unclear on only one inclusion criteria, we included the article in the second screening. Two authors (H.C. and C.G.) then reviewed the full-text of articles that passed the first screening to confirm that all inclusion criteria were met.
One author (H.C.) applied the same selection criteria for both the title/abstract and full-text screening for articles in the references of eligible papers from the original MEDLINE/PubMed, Embase, and Scopus databases.
All included articles met four inclusion criteria: (1) English, (2) HIC context (determined by World Bank high-income economies, including the United States, Canada, Australia, and certain countries in Europe and Asia), and (3) about research participants who are uninsured or low-income, which limits their access to healthcare, and in biomedical clinical research that either had the prospect of direct medical benefit or was offered to them on the basis of their ill health; (4) recognizes and/ or addresses challenges and/or ethical considerations of uninsured or low-income participants in biomedical clinical research.
We excluded articles if they met any of three exclusion criteria: (1) letters, books, and book reviews; (2) studies about or involving research participants who are in marginalized or minority groups that are more likely to be uninsured or low-income, but focus on challenges and barriers due to characteristics such as minority status and not insurance or income; and (3) studies about or involving research participants in nonbiomedical or healthy volunteer trials without prospect of benefit. Although the uninsured are often discussed in the context of non-biomedical or healthy volunteer trials, we excluded these trials because the ethically salient issues for participants receiving medical care or benefit differ from issues raised by trials in which participants cannot reasonably expect such care or are not seeking medical benefit. For example, bioethicists worry about payment and possible undue inducement of healthy volunteer research participants, who are usually motivated by money. 33, 34 Payment may be less of a factor for participants who join research in order to access healthcare, and other factors (e.g. desire for healthcare, provision of ancillary care or post-trial care) may be more likely to affect ethical analyses on how to recruit, enroll, and treat this particular group of uninsured participants. Moreover, the moral imperative to include uninsured participants who are ill in therapeutic trials-or to not unjustly exclude them for their ''protection''-differs from that of participants in nontherapeutic or non-biomedical trials.
Data extraction
One author (H.C.) independently extracted data from the studies that met our inclusion criteria into standardized tables (Tables 2-4). All authors reviewed and agreed upon the analysis of the data. Excluded articles included studies not about high-income countries (n = 2), studies that did not acknowledge challenges or ethical considerations (n = 5), studies that focused on minority populations without considering the impact of uninsurance or low-income (n = 6), and studies not about participants in biomedical trials that either had a prospect of direct medical benefit or was offered to them on the basis of their ill health (n = 9). Some of the excluded articles fit into more than one of these categories. Those articles were categorized by their primary reason for exclusion. b Three primary articles were part of the systematic reviews included, and the Ford et al. 31 systematic review was included in the Bonevski et al. 32 systematic review. We included these articles because we wanted to capture the amount of attention paid to the challenges and ethical considerations of working with the uninsured and low income in research, and because the primary papers and the systematic reviews framed themselves in unique ways.
Included articles fell into two broad categories: (1) conceptual papers that discuss ethical treatment of uninsured or low-income participants at various stages of biomedical clinical research in HIC or (2) empirical papers on the perspectives of the uninsured or lowincome on clinical trials or on the barriers of enrolling and/or retaining uninsured or low-income participants. We further categorized the conceptual and empirical articles by the stage of research they discussed: enrollment and retention (Table 2) , treatment during the course of research (Table 3) , or post-trial responsibilities (Table 4) .
We further extracted themes from each of the articles included in our review. Themes regarding ''enrollment and retention'' included barriers for enrollment and retention, informed consent, financial incentives, exploitation, and undue inducement among others. Although retention refers to treatment during the course of research, we grouped it with enrollment because the papers that addressed one often addressed the other. Themes regarding ''treatment during the course of research'' included considerations such as ancillary care and compensation for research-related harms for purposes other than retention. Themes regarding ''post-trial responsibilities'' included posttrial care and access.
Results
The searches generated a total of 974 results from PubMed/MEDLINE (551), Embase (117), and Scopus (366). After removing duplicates, 797 unique publications remained. Of the 797 results, 27 passed an initial title/abstract screening and were read in full. In all, 12 articles were excluded because they either met one of the three exclusion criteria or because they did not meet all four inclusion criteria, leaving 15 eligible articles ( Figure 1) .
A total of 19 articles were extracted from the references of the 15 articles via a title/abstract screening. Eight of the 19 ultimately passed the full-text screening and were included in our review for a total of 23 articles ( Figure 1 ).
Characteristics of reviewed articles
Of the 23 results, there were 13 empirical articles and 10 conceptual articles. Ten of the 13 empirical articles involved uninsured or low-income participants, and the remaining three empirical articles were literature reviews of barriers to enrollment and/or retention in clinical research of disadvantaged or underrepresented groups (including uninsured and low-income; 31, 32, 35 Table 1 ). The reviews did not focus solely on the uninsured or low-income, and/or looked at a different subset of clinical trials.
Eight of the 10 conceptual articles reviewed challenges or ethical considerations of involving uninsured or low-income research participants in biomedical clinical research. Two were newspaper or magazine articles, published in The New York Times 45 and The Scientist 46 respectively ( Table 1 ). The majority (n=19) of the articles in our review discussed enrollment and retention of uninsured or low-income participants. 31, 32, 35, [37] [38] [39] [40] [41] [42] [43] [44] [45] [47] [48] [49] [50] [51] [52] [53] Considerably fewer articles discussed treatment of these participants during the course of research (n=5) 1,2,36,39,52 or post-trial responsibilities owed to uninsured or low-income participants (n = 4) 1, 39, 45, 46 ( Table 3) . Three papers 1,39,45 discussed more than one of these issues.
Enrollment and retention
Most of the papers (19/23) in our review described challenges and ethical considerations of enrollment and retention. Eleven 31, 32, 35, [37] [38] [39] [40] [41] [42] [43] [44] of the 19 papers were empirical studies, and eight 45, [47] [48] [49] [50] [51] [52] [53] were conceptual studies ( Table 2) .
The empirical papers on enrollment and retention identified several barriers to enrolling uninsured and low-income groups, both independent of and associated with other demographic factors ( Table 2) . Eight papers 31, 32, 35, 38, [40] [41] [42] 44 explicitly mentioned that uninsured or low-income participants should be enrolled. Of the eight, six 32, 35, 38, 41, 42, 44 gave reasons of scientific validity, five 31, 32, 38, 40, 41 gave reasons of benefiting or addressing disparate health outcomes for groups with greatest burden of disease, and two 31, 32 gave reasons of fair access to trial benefits. Barriers to enrollment included limited access to primary or preventive care due to uninsurance or low-income, which led to later diagnoses and development of comorbid conditions that met exclusion criteria, lack of access to institutions conducting trials or to physicians with enough time or knowledge about trials, and overall lack of trust in the government, research, or medical Focus group 3 38, 39, 40 Systematic review 3 31, 32, 35 Other descriptive study 4 [41] [42] [43] [44] Conceptual article 10 (43%) News article 2 45, 46 Review article 8
1,47-53 system. 31, 32, 35, 38, 41, 42, 44 Logistical issues such as lack of time, transportation, or daycare services for children constituted barriers for both enrollment and retention of uninsured or low-income participants in clinical research. 31, 32, 37, 38, 41, 44 One paper 43 cited informed consent bias as a potential barrier.
Two papers, Grady et al. 39 and Slomka et al., 37 discussed ways to promote uninsured or low-income participation in clinical research. Grady et al. 39 focused on respect for participants, while Slomka et al. 37 focused on financial incentives.
Interestingly, the focus group and patient interview studies 37, [38] [39] [40] found that uninsured or low-income communities were willing to participate in biomedical clinical research despite logistical, structural, and personal barriers to enrollment. Given the difficulty of enrolling and retaining low-income groups despite willingness to participate, Webb et al. 44 and Humphreys and Weisner 42 suggest study design (i.e. exclusion criteria) may be disproportionally excluding uninsured, low-income, or minority patients.
To address barriers to both enrollment and retention, eight studies propose strategies such as financial assistance for transportation or time spent in research (n = 4), 32, 35, 41, 44 collaboration with the community or community leaders to improve trust (n = 7), 32, 35, [37] [38] [39] 41, 44 reminder calls (n = 2), 32,44 financial incentives (n = 5), 32, 35, 37, 40, 44 and monitoring of medical welfare throughout the trial (n = 2).
32,39
The eight conceptual papers on enrollment and retention discussed concerns about whether or not to enroll (n = 6), 45, 47, [49] [50] [51] 53 informed consent (n = 6), 45 47 Merrill, 49 and Pace et al. 50 explicitly argued for the inclusion of uninsured and low-income participants in cancer, AIDS, and general clinical trials, respectively. Welsh et al. 53 argued for inclusion of minority groups that are more likely to face economic barriers. Guerrero and Heller 48 and Vasgird et al. 52 raised issues about informed consent due to power dynamics between patients and physicians, exploitation, undue inducement, and lack of compensation for research-related harms.
Treatment during the course of research
Five of 23 papers mentioned ethical considerations regarding the treatment of uninsured and low-income participants during the course of research, specifically ancillary care (n = 4) 1,2,36,39 and compensation for research-related harms (n = 1) 52 (Table 3) . Three 2, 36, 39 of five were empirical, and two 1,52 were conceptual. The three empirical papers stated or hypothesized that uninsured or low-income people expected ancillary care during research participation. Jacobson et al. 2 found that low-income participants would not participate in research without ancillary care provision, and Grady et al. 39 reported that representatives from lowincome, urban communities in the United States saw ancillary care throughout the course of research as necessary to respect participants.
None of the empirical papers proposed when or how much ancillary care to provide. In fact, Jacobson et al. 2 raised a concern that providing ancillary care could exacerbate participants' misunderstanding of the purpose of research as treatment or potentially be a form of coercion of low-income participants. Koblin et al. 36 suggested that unrealistic expectations of ancillary care may be a problem for uninsured participants that must be adequately addressed before enrolling them. However, one conceptual paper, Dal-Re´et al., 1 proposed ancillary care as a method to ensure a fair level of benefits to participants who lack access to healthcare.
The other conceptual paper about treatment of uninsured and low-income participants during the course of research, Vasgird et al., 52 focused on compensation for research-related harms, arguing that without compensation for research-related harms, uninsured participants remain vulnerable during the course of research participation.
Post-trial care and access
Four papers mention post-trial access (n = 3) 1,39,45 or post-trial care (n = 2) 39,46 for uninsured or low-income research participants (Table 4) . Three of the four papers were conceptual, two of which were newspaper or magazine articles.
Clemmitt 46 suggested that research community members believed that ongoing medical care post-trial was required to ethically enroll low-income participants. Grady et al. 39 described how representatives of low-income communities raised concerns about posttrial access to medications and healthcare in general for uninsured research participants. These representatives stated that trials should have post-trial plans to adequately provide care to uninsured participants, even if that means the research team has to continue to provide that care. Kolata and Eichewald 45 raised concerns about lack of post-trial access for uninsured research participants due to potential health consequences of terminating treatment, while Dal-Re´et al. 1 proposed post-trial access to experimental medications as another strategy to provide a fair level of benefits to participants who are uninsured or otherwise lack access to healthcare.
Discussion
Limitations
The review has several limitations. First, the ''uninsured'' consists of a diverse group of people who lack access to healthcare to various extents and for various reasons, have different needs, and require different ethical considerations in clinical research. Second, many studies in our review focus on minority or marginalized groups (e.g., African-Americans, Latino women, homeless, drug addicts) who are more likely to be uninsured or broadly study low-income, socioeconomically disadvantaged groups. Thus, many of the ethical considerations discussed apply not just to uninsured participants but also to underinsured or other marginalized participants. Third, some existing studies that do discuss exploitation, ancillary care, and post-trial access were excluded because they focus on LMIC or on paying healthy volunteers, and do not recognize the particular circumstances of the uninsured seeking healthcare through research in HIC. 3, 33, 34, 54 Fourth, the majority (20/ 23) 2,35--53 of our studies address US participants only, leaving out other HIC some of which have different healthcare systems. Finally, our review focuses on biomedical clinical research, and not on the ethical treatment of uninsured research participants in trials such as nonvaccine healthy volunteer studies, non-treatment community-based research such as survey studies, public health research, or natural history studies. These types of research raise different ethical issues that should be analyzed separately, and may be areas for future research.
Implications and future research
This scoping review reveals the lack of attention to the ethics of clinical research in HIC with uninsured and low-income people who are seeking healthcare. The articles in this review, although limited in number, seem to agree that uninsured persons should be included in research, and that special consideration might be needed in informed consent, financial compensation, ancillary care, compensation for research-related injury, and post-trial responsibilities. However, there are significant gaps in both data and thoughtful analysis on how to ethically involve uninsured research participants in biomedical clinical research offered to them on the basis of their ill health or with a prospect of direct medical benefit.
Building on the literature and gaps identified by this systematic review, we propose future research to begin to address three broad questions (Table 5 ).
1. What is the current status of the uninsured research participant in biomedical clinical research?
The articles in this review do not make clear how often uninsured participants are enrolled in treatment or vaccine trials or how they are treated during research participation. Inconsistencies exist between included articles, with some suggesting low rates of research participation of the low-income and uninsured and others suggesting an increasing rate of participation, and several noting that no clear picture exists. However, it is not unreasonable to think that the uninsured face barriers in accessing clinical trials. Some authors from the 1990s cancer literature noted that even patients with insurance were prevented from enrolling in cancer clinical trials because of costs and insurance reimbursement policies. 55 Future research should try to elucidate the enrollment rate of uninsured and low-income participants in treatment or vaccine trials, and whether there are particular types of trials uninsured participants are more likely to be enrolled in or excluded from. The latter is especially important since data suggest that certain minority groups are more likely to be enrolled in phase I healthy volunteer trials than in later phase treatment trials. 56 Similarly, given the increasing private sponsorship of clinical trials in the United States, 57 looking at uninsured participants in publicly funded versus privately funded trials could address interesting ethical questions such as (1) Are uninsured participants more likely to enroll in trials sponsored by pharmaceutical companies or by public sponsors? (2) Are they treated differently (e.g., insurance coverage, ancillary care or post-trial care provision) in these trials? And, (3) are there ethical differences in what uninsured participants are owed based on the funding source of a trial?
There are also no available data about what happens when those who are uninsured are injured in research or suffer an adverse event, nor the extent to which researchers pay attention to issues of uninsurance and income in transitioning participants to needed healthcare at the end of a study.
Moreover, we do not know whether or to what extent research institutions and investigators take healthcare access into account when deciding about enrollment, ancillary care, or post trial care. Similarly, do certain institutional policies or protocols exclude participants based on health insurance status? Do any provide medical care or coverage of medical costs (and which ones) for their research participants? Do the composition and attitudes of the institution's staff affect enrollment of uninsured patients in clinical trials? 58 Given the possibility that socioeconomic status could independently affect willingness and ability to participate in trials, 41, 45 future research should also look at the effects of insurance and income on research participation independently of other demographic factors such as race or gender or the interaction of these factors. 58 Gathering data about the current status of the uninsured in research may also begin to answer other research questions about how uninsured participants are and should be treated during and after research.
2. How should uninsured research participants be treated during and after clinical research?
The broader literature on relevant ethical issues like ancillary care and post-trial access does not focus on the uninsured or on HIC. 3, 54 Little has been written about similarities or differences between research participants or lack of healthcare access in LMIC and HIC. These comparisons could inform how we treat or should treat research participants who lack access to healthcare in HIC. For example, Jacobsen et al. 2 proposed collecting data on ancillary care practices in HIC using the descriptive methodologies used in LMIC and comparing the findings.
Moreover, attention to post-trial responsibilities, a relatively recent idea introduced by the Declaration of Helsinki (2000), is still sparse in any context. Conceptual papers could address any particular considerations in determining post-trial responsibilities to research participants who are uninsured or otherwise lack access to healthcare access in HIC.
A better understanding of the ethics of enrolling uninsured participants and how they should be treated during and after biomedical clinical research may also help to influence guidance and policies on compensation for research-related harms, ancillary care, and post-trial care.
3. How, if at all, should additional protections for uninsured research participants affect their enrollment?
Many existing ethical discussions about the uninsured and low-income in research took place in the late 1990s and early 2000s, as evidenced by the dates of the papers in our review. However, both healthcare and clinical research have changed significantly in the past decade. Uninsurance rates in the United States, which reached their peak in 2013 prior to Medicaid expansion and other Affordable Care Act changes, have started to rise again. 14, 17 One challenge is balancing fair participant selection and concerns about scientific validity with concerns about undue inducement when offering Table 5 . Proposed research agenda for biomedical research with uninsured research participants in high-income countries.
participants access to healthcare services that they otherwise cannot access. How should possible exploitation be considered when determining who to enroll in a study? Should financial compensation or ancillary care for uninsured or low-income participants be different from other enrollees, how would such differences be justified, and how can we prevent both exploitation and undue inducement? Addressing these questions would expand the existing literature on undue inducement and exploitation, which preferentially focuses on payment rather than other benefits, or on healthy volunteers rather than low-income participants primarily seeking healthcare access. 33, 34, [59] [60] [61] Findings from our scoping review have potential implications beyond setting a research agenda. Research teams conducting biomedical clinical research in HIC should pay more attention to the existence (or lack thereof) of uninsured or low-income participants in their trials. The themes identified and discussed by the reviewed articles may help teams assess their treatment of participants who are uninsured or otherwise lack access to healthcare and make changes to ensure that their studies remain ethical. Paying more attention on both a broad and individual level to the plight of the uninsured and underinsured may help improve the treatment of vulnerable and forgotten participants caught in the throes of a healthcare crisis.
Conclusion
Overall, our review reveals a lack of attention to uninsured and low-income individuals in the research context, and even less attention on the salient ethical issues of including uninsured and low-income participants in biomedical clinical research. despite this, there are many important ethical questions and challenges that should be addressed especially in the current climate of healthcare access in the United States. We hope that by elucidating the dearth of empirical and theoretical research, we will prompt additional studies guided by our proposed research agenda that may lead to future practices and protections regarding uninsured and lowincome research participants. 
